A Pharmacokinetic and Phase II Study of Pertuzumab in Combination With Trastuzumab And Eribulin (Halaven) in Patients With Advanced HER2-Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 14 Jun 2016 Status changed from discontinued to completed.
- 29 Jul 2015 Status changed from recruiting to suspended as per University Hospital Medical Information Network - Japan record.
- 10 Jan 2014 Status changed from not yet recruiting to recruiting according to UMIN record.